Men's Active
Man in a striped shirt and loosened tie using an injection pen on his abdomen
© Adobe Stock / #894317853
Newsletter · Weight loss · Fat loss

What the semaglutide trials show about weight loss, muscle and stopping the drug

The weekly injection behind Wegovy produced an average weight loss of almost 15 percent in its main trial. The fine print covers lean mass, side effects and what happens after the last dose.

By Men's Active··2 min read

Semaglutide mimics GLP-1, a gut hormone that slows stomach emptying and reduces appetite. At a dose of 2.4 mg once a week it is approved for weight management in many countries under the brand name Wegovy. It is a prescription medicine for people with obesity, or with overweight and a related health problem.

The key trial, STEP 1, was published in 2021 in the New England Journal of Medicine, led by John Wilding of the University of Liverpool. It randomised 1,961 adults with obesity or overweight, without diabetes, to semaglutide or placebo for 68 weeks. Both groups also received lifestyle counselling.

What they found

  • Average weight loss was 14.9 percent with semaglutide and 2.4 percent with placebo.
  • In a subgroup scanned by DXA, total fat mass fell by about 19 percent and visceral fat, the fat around the organs, by about 27 percent. Lean mass also fell in absolute terms, although it made up a larger share of body weight at the end.
  • Gastrointestinal side effects, mostly nausea, diarrhoea and constipation, were common. They led 4.5 percent of the semaglutide group to stop treatment, against 0.8 percent on placebo.

A follow-up of 327 participants, published in 2022 in Diabetes, Obesity and Metabolism, looked at what happened when treatment ended. One year after stopping semaglutide and the lifestyle programme, participants had regained about two-thirds of the weight they had lost.

How to apply it

  • Semaglutide is a medical treatment. The decision to use it belongs with a doctor, based on health risks, not appearance.
  • Anyone taking it should prioritise protein and strength training. Lean mass is lost alongside fat, and resistance exercise is the main way to protect it.
  • Treat it as long-term management. The extension data suggest weight returns for most people once the drug stops.
  • Avoid products sold without prescription online. Their content and dose cannot be verified.

A note on the evidence

STEP 1 was large, randomised and placebo-controlled, but it was funded by Novo Nordisk, the drug's manufacturer. The body composition data come from a subgroup, and the withdrawal analysis was exploratory. Long-term outcome data are still accumulating.

Sources

  • Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
  • Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.

More from Men’s Active+

See all stories →